γ-Aminobutyric acid type A receptors (GABA_ARs) are the principal inhibitory neurotransmitter receptors in the mature central nervous system (CNS) that play essential roles in regulating neuronal excitability. The GABRA1 gene, which encodes the α1 subunit of the GABA_ARs, represents a critical nexus in CNS inhibitory neurotransmission. Pathogenic missense variants within this gene are predominantly associated with a spectrum of neurodevelopmental disorders, such as epilepsy, developmental delay, and neurodevelopmental encephalopathies. These pathogenic variants typically alter receptor function bidirectionally, resulting in either a gain-of-function (GOF) or a loss-of-function (LOF) phenotype.

In a recent Genes & Diseases study, researchers from University of British Columbia, Shenzhen University of Advanced Technology, Fudan University, and Chongqing Medical University performed a comprehensive functional and clinical characterization of pathogenic GABRA1 missense variants, addressing a major challenge in the field: accurately distinguishing gain-of-function (GOF) and loss-of-function (LOF) variants and correlating these functional effects with patient phenotypes.

Previous studies commonly classified GABRA1 variants based primarily on changes in the half-maximal effective concentration (EC50) of GABA. However, this single-parameter approach fails to capture the overall functional consequences of receptor alterations, particularly when variants substantially affect maximal receptor responses. To overcome these limitations, the researchers developed a novel classification framework that integrates both GABA sensitivity and maximal receptor activity, providing a more comprehensive assessment of variant function.
Using electrophysiological analyses in a recombinant HEK293 expression system, the study functionally evaluated 23 previously uncharacterized and 6 previously reported GABRA1 missense variants. The investigators introduced a novel two-parameter "functional polarity" score based on the ratio of mutant-to-wild-type receptor responses measured at the wild-type EC50 concentration. By incorporating both EC50 shifts and maximal response amplitudes, this strategy enabled more accurate discrimination between GOF and LOF variants than conventional approaches, where a ratio >1 signifies GOF and a ratio <1 signifies LOF.

This method also resolved instances in which classification based solely on EC50 changes produced misleading conclusions regarding receptor activity. Specifically, variants such as T257R and A281V, previously classified as GOF due to left-shifted EC50 values, were reclassified as LOF because their significantly diminished maximal responses prevented sufficient chloride influx. Among the 61 analyzed variants, the majority (42/61) were identified as LOF, with a high concentration of these mutations residing in the extracellular N-terminal domain. Conversely, GOF variants were predominantly located within the transmembrane domains (TM1–TM3), suggesting that mutations in these regions are more likely to disrupt channel gating and enhance receptor activity.

Clinical implications derived from a cohort of 117 patients revealed distinct genotype-phenotype correlations based on these functional classifications. LOF variants were linked to a higher incidence of seizures and increased sensitivity to fever, suggesting that reduced inhibitory signaling predisposes patients to hyperexcitability and seizure susceptibility. In contrast, GOF variants were more frequently associated with severe cognitive impairment and movement disorders, indicating that excessive receptor activity may disrupt normal neuronal network development and function through distinct pathogenic mechanisms.

In conclusion, this study provides a more precise and reliable framework for the functional characterization of GABRA1 variants by integrating efficacy and potency into a unified response ratio metric. Importantly, the authors emphasize the translational significance of precise functional classification. Because therapeutic responses may differ depending on whether a variant increases or decreases receptor function, accurate determination of GOF or LOF status is critical for precision medicine approaches. The proposed two-parameter framework offers a more reliable foundation for variant interpretation, clinical diagnosis, and treatment selection in patients with GABRA1-associated neurological disorders.

Reference
Title of the original paper: Systemic characterization of pathogenic GABRA1 missense variants

Journal Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2026.102135

Funding Information:
Canadian Institutes of Health Research (CIHR), Canada Project Grant (No. FRN-190294)
Shenzhen Medical Research Fund (China) (No. B2302001, D2403004)
Shenzhen Science and Technology Program (China) (No. KQTD20210811090117032, JCYJ20220818101615033)
NSFC-Guangdong Joint Fund (China) (No. U20A6005)
Research Fund for International Scientists of National Natural Science Foundation of China (No. 82350710223)
Partially funded by SANS-Shanghai Academy of Natural Sciences.

# # # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus CiteScore: 10.4 | Impact Factor: 14.6

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #